Showing results (1771-1780 of 2,171) with videos related to
Sort By:
Pageof 218
The Journal of Dermatological Treatment|August 5, 2021
Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE studyAndrew Blauvelt, April W Armstrong, Richard G Langley, et al.Journal of Drugs in Dermatology : JDD|August 2, 2024
Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus PanelJoshua Burshtein, Milaan Shah, Danny Zakria, et al.Clinical Chemistry|May 15, 2007
6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trialMax Reinshagen, Ekkehard Schütz, Victor W Armstrong, et al.ACS Nano|August 23, 2021
Water-Borne Nanocoating for Rapid Inactivation of SARS-CoV-2 and Other VirusesValentin A Bobrin, Sung-Po Chen, Carlos Fitzgerald Grandes Reyes, et al.American Heart Journal|July 12, 2011
Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: observations from "Assessment of Pexelizumab in Acute Myocardial Infarction"John K French, Paul W Armstrong, Eric Cohen, et al.RMD Open|June 28, 2019
Understanding the association between skin involvement and joint activity in patients with psoriatic arthritis: experience from the Corrona RegistryPhilip J Mease, Carol J Etzel, William J Huster, et al.Journal of the American College of Cardiology|June 1, 1996
Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 InvestigatorsL K Newby, W R Rutsch, R M Califf, et al.American Heart Journal|June 5, 2017
Characterization of hemodynamically stable acute heart failure patients requiring a critical care unit admission: Derivation, validation, and refinement of a risk scoreIsmail R Raslan, Paul Brown, Cynthia M Westerhout, et al.Circulation|August 20, 2003
Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trialKenneth W Mahaffey, Christopher B Granger, Jose C Nicolau, et al.Circulation. Cardiovascular Quality and Outcomes|May 17, 2012
Transfer times and outcomes in patients with ST-segment-elevation myocardial infarction undergoing interhospital transfer for primary percutaneous coronary intervention: APEX-AMI insightsSean van Diepen, Petr Widimsky, Renato D Lopes, et al.Pageof 218